ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.20 USD
+0.25 (0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.20 USD
+0.25 (0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth A Momentum A VGM
Zacks News
Roche's Breast Cancer Study Meets Co-Primary Endpoint
by Zacks Equity Research
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Celgene's Luspatercept Meets Primary Endpoint in the Study
by Zacks Equity Research
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Medicines Company's Inclisiran Studies to Continue Unmodified
by Zacks Equity Research
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
Infinity and Arcus Ink Deal for Two Triple Combo Studies
by Zacks Equity Research
: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.
Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote
by Zacks Equity Research
Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies
by Zacks Equity Research
Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
by Zacks Equity Research
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
Pfizer's Breast Cancer Drug Misses Overall Survival in Study
by Zacks Equity Research
Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.
Merrimack Crashes as Phase II Pancreatic Cancer Study Fails
by Zacks Equity Research
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.
Novo Nordisk (NVO) Announces Results in Diabetes Studies
by Zacks Equity Research
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
Anika Reports Top Line Data from CINGAL Study, Shares Slump
by Zacks Equity Research
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
by Zacks Equity Research
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Alexion (ALXN) Submits Application for ALXN1210 with FDA
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
Roche to Buy Rest of Foundation Medicine for $2.4 billion
by Zacks Equity Research
Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.
4 Undervalued MedTech Stocks to Consider Amid Volatility
by Zacks Equity Research
Amid turbulences of the U.S. market, some value stocks of MedTech industry appear to be lucrative investment options.
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
by Zacks Equity Research
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
Sarepta Inks Manufacturing Deal for Gene Therapy Program
by Zacks Equity Research
Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.
Here's Why Sarepta is Up More Than 60% So Far This Year
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.
BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
by Zacks Equity Research
BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.
INSYS Gets Negative FDA Recommendation for Pain Candidate
by Zacks Equity Research
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?
by Zacks Equity Research
Let's put ANI Pharmaceuticals (ANIP) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Pfizer Hikes Dividend, Announces $10B Share Buyback Plan
by Zacks Equity Research
Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.